Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
01
09
2018
accepted:
03
01
2019
pubmed:
8
1
2019
medline:
17
6
2020
entrez:
8
1
2019
Statut:
ppublish
Résumé
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer. It is defined by cholangiocytic differentiation and has poor prognosis. Recently, epigenetic processes have been shown to play an important role in cholangiocarcinogenesis. We performed an integrative analysis on 52 iCCAs using both genetic and epigenetic data with a specific focus on DNA methylation components. We found recurrent isocitrate dehydrogenase 1 (IDH1) and IDH2 (28%) gene mutations, recurrent arm-length copy number alterations (CNAs), and focal alterations such as deletion of 3p21 or amplification of 12q15, which affect BRCA1 Associated Protein 1, polybromo 1, and mouse double minute 2 homolog. DNA methylome analysis revealed excessive hypermethylation of iCCA, affecting primarily the bivalent genomic regions marked with both active and repressive histone modifications. Integrative clustering of genetic and epigenetic data identified four iCCA subgroups with prognostic relevance further designated as IDH, high (H), medium (M), and low (L) alteration groups. The IDH group consisted of all samples with IDH1 or IDH2 mutations and showed, together with the H group, a highly disrupted genome, characterized by frequent deletions of chromosome arms 3p and 6q. Both groups showed excessive hypermethylation with distinct patterns. The M group showed intermediate characteristics regarding both genetic and epigenetic marks, whereas the L group exhibited few methylation changes and mutations and a lack of CNAs. Methylation-based latent component analysis of cell-type composition identified differences among these four groups. Prognosis of the H and M groups was significantly worse than that of the L group. Conclusion: Using an integrative genomic and epigenomic analysis approach, we identified four major iCCA subgroups with widespread genomic and epigenomic differences and prognostic implications. Furthermore, our data suggest differences in the cell-of-origin of the iCCA subtypes.
Identifiants
pubmed: 30615206
doi: 10.1002/hep.30493
pmc: PMC6594081
doi:
Substances chimiques
IDH2 protein, human
EC 1.1.1.41
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2091-2106Subventions
Organisme : European Union's Horizon 2020 Research and Innovation Program
ID : 667273
Pays : International
Organisme : Helmholtz Foundation
Pays : International
Organisme : German Research Foundation
ID : CRC SFB/TR 209
Pays : International
Informations de copyright
© 2019 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases.
Références
Hepatology. 1999 Jun;29(6):1858-62
pubmed: 10347130
Epigenetics. 2006 Jan-Mar;1(1):55-60
pubmed: 17998806
Hepatology. 2008 May;47(5):1544-56
pubmed: 18393293
Gastroenterology. 2009 Mar;136(3):1012-24
pubmed: 19150350
Bioinformatics. 2009 Nov 15;25(22):2906-12
pubmed: 19759197
Genes Dev. 2010 Aug 1;24(15):1580-9
pubmed: 20679392
World J Hepatol. 2010 Dec 27;2(12):419-27
pubmed: 21191517
Nature. 2011 Jan 27;469(7331):539-42
pubmed: 21248752
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Epigenomics. 2009 Oct;1(1):177-200
pubmed: 22122642
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Genome Res. 2012 May;22(5):837-49
pubmed: 22391556
Hum Pathol. 2012 Oct;43(10):1552-8
pubmed: 22503487
Nat Genet. 2012 May 06;44(6):690-3
pubmed: 22561520
Oncogene. 2013 Jun 20;32(25):3091-100
pubmed: 22824796
Curr Opin Neurobiol. 2012 Oct;22(5):762-7
pubmed: 22835699
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Oncogene. 2014 May 22;33(21):2807-13
pubmed: 23770855
PLoS One. 2013 Oct 17;8(10):e77553
pubmed: 24147022
Carcinogenesis. 2014 Mar;35(3):670-82
pubmed: 24148822
Nat Genet. 2013 Dec;45(12):1470-1473
pubmed: 24185509
Nat Genet. 2013 Dec;45(12):1474-8
pubmed: 24185513
Acta Biochim Biophys Sin (Shanghai). 2014 Mar;46(3):180-9
pubmed: 24389645
Mod Pathol. 2014 Aug;27(8):1163-73
pubmed: 24406866
Nature. 2014 Jun 26;510(7506):537-41
pubmed: 24847876
J Cancer. 2014 Oct 28;5(9):790-6
pubmed: 25368680
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Oncotarget. 2015 Feb 10;6(4):2466-82
pubmed: 25537518
Oncogene. 2015 Sep 24;34(39):5095-104
pubmed: 25597408
Cancer Cell. 2015 Mar 9;27(3):382-96
pubmed: 25759023
BMC Cancer. 2015 Mar 14;15:126
pubmed: 25879652
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
Nat Rev Cancer. 2015 Nov;15(11):653-67
pubmed: 26493646
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
Nature. 2016 Jan 7;529(7584):110-4
pubmed: 26700815
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Cancer Discov. 2016 Jul;6(7):727-39
pubmed: 27231123
Tumour Biol. 2016 Nov;37(11):14757-14764
pubmed: 27629143
Sci Rep. 2016 Nov 23;6:37393
pubmed: 27876760
Cell Rep. 2017 Mar 14;18(11):2780-2794
pubmed: 28297679
Genome Biol. 2017 Mar 24;18(1):55
pubmed: 28340624
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1423-1434
pubmed: 28645654
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Ann Gastroenterol. 2018 Jan-Feb;31(1):42-55
pubmed: 29333066
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
BMC Genomics. 2018 Jun 5;19(1):440
pubmed: 29871612
Hepatology. 2019 Feb;69(2):622-638
pubmed: 30102768